DV
Therapeutic Areas
Basilea Pharmaceutica Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Cresemba® (isavuconazole) | Invasive fungal infections | Approved/Commercial |
| Zevtera® (ceftobiprole medocaril) | Bacterial infections | Approved/Commercial |
| Ceftibuten-ledaborbactam | Bacterial infections (novel antibiotic) | Clinical Development |
| Preclinical Anti-infective Assets | Severe bacterial or fungal infections | Preclinical |
| Clinical Anti-infective Assets | Severe bacterial or fungal infections | Clinical |